Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEGPH20 plus nab-paclitaxel/gemcitabine versus placebo plus nab-paclitaxel/gemcitabine in hyaluronan-high metastatic pancreatic cancer
NL-OMON47683Phase 3Active, not recruiting
- Sponsor
- Halozyme Therapeutics, Inc.
- Start
- Mar 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pegvorhyaluronidase alfa in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PC) (2 arms), sponsored by Halozyme Therapeutics, Inc. Primary endpoint: Overall survival. Started Mar 2017; status: active, not recruiting.
02
Drugs
pegvorhyaluronidase alfa
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NL-OMON47683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47683.